drugset
drugset / Trial / NCT03027102

Study of Allogeneic Double Negative T Cells (DNT-UHN-1) in Patients With High Risk Acute Myeloid Leukemia

NCT03027102 ↗

Phase 1 Completed 7 enrolled University Health Network, Toronto Ozmosis Research Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study aims to determine the safety and toxicity of incremental doses of Double Negative T (DNT) cells in human subjects with high risk acute myeloid leukemia (AML). DNT cells are mature T lymphocytes that comprise \~1% of white blood cells in humans. Injection of DNTs from healthy donors has been demonstrated to be effective against AML cells. DNT cells will be collected from healthy volunteers and injected into patients.

Timeline

Start
2017-08-15
Primary completion
2024-12-10
Completion
2024-12-10

Drugs

EvaluationDrugModalityDoseRoute
Subject DNT cells Cell therapy — —

Indications

acute myeloid leukemia